Who is Island Pharmaceuticals?
Island Pharmaceuticals (ASX: ILA) is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections.
We have a lead asset, ISLA-101, that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.
Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% people with the disease do not present with symptoms, enabling the virus to spread within communities. The impact of warming global climates are accelerating the presence of mosquito-borne viruses and expanding the reach and concern over mosquito borne viruses.
Why invest in Island Pharmaceuticals?
Island’s business model is to repurpose drugs, like ISLA-101, and partner with biotech or pharmaceutical companies for commercial gain.
Island’s lead asset ISLA-101 is a repurposed drug, which should allow Island a much faster, less costly and less risky path to market compared to traditional drug development. Initially developed as a potential cancer drug by a large pharmaceutical company, ISLA-101 has already been through 48 Phase I and II clinical trials before being repurposed. It has also been verified as safe for clinical trials in humans by multiple regulators, including the United States Food and Drug Administration (FDA).
Priority Review Vouchers, a voucher system created and managed by the (PRVs) Federal Food, Drug, and Cosmetic Act (FD&C Act), section 524, authorises FDA to award to sponsors of approved tropical disease product applications that meet certain criteria. Island is looking at several PRV opportunities related to ISLA-101.
Island also has strong collaborative relationships with Monash and Griffith University that give Island access to libraries of compounds which may be repurposed for areas of unmet need.
Island is led by a highly capable, experienced management team, Board of Directors and Scientific Advisory Board with extensive expertise in drug repurposing and development, infectious diseases and executing successful commercial transactions.
Which stock exchange is Island Pharmaceuticals listed on?
Island Pharmaceuticals is listed on the Australian Securities Exchange (ASX.)
What is Island Pharmaceuticals ticker code?
Island trades under the ticker code: ILA
I do not live in Australia can I still buy stock in Island Pharmaceuticals?
Offshore investors can trade in Island stock through certain global brokers which offer international (and Australian) share trading and custodial facilities.
Brokerage costs and terms vary greatly, and some brokers may only provide a custodial note or an International Depository Receipt (IDR), a negotiable certificate issued by a bank. IDRs represent ownership of shares for a particular stock in a foreign company, that the bank holds in trust. Many custodial notes and IDRs over shares will not give you full ownership; they may offer you ownership minus dividends and voting rights. Therefore, please check terms and conditions you have agreed to before trading.
Remember you may have to pay more because investing in international stocks, you’ll be transacting in foreign currencies. For example, if you are trading on the Australian Securities Exchange, you must pay the brokerages in the Australian dollars. Also, you may be required to pay an annual/monthly maintenance charge that may also be higher, compared to domestic accounts.
In some counties there are limitations as to how much you re allowed to own of foreign shares. For example, in India: up to $250,000 can be invested overseas by Indian residents. As per the RBI notification in the Liberalised Remittance Scheme (LRS), an Indian resident individual can only invest up to $250,000 overseas per year.
Some examples of US / global brokers that can trade in Island Pharmaceuticals stock are:
XTB online trading
For more information on how to find the right broker, visit the ASX website at www.asx.com.au. Alternatively, contact our Investor Relations team by emailing: firstname.lastname@example.org or phone: +61 411 117 774.
What else should I be aware of?
Besides the above factors, you also need to keep in mind the foreign stock risks. As these stocks will be listed on foreign stock exchanges – the environment and the factors (like local government policies, local trends, etc) can affect the share price of Island.
Is there a minimum number of shares I need to purchase to become a shareholder?
The minimum initial share purchase is $500 under ASX listing rules. Island Pharmaceuticals suggests that individuals discuss the purchase of any shares with a financial advisor or broker to determine what the optimal number to buy would be considering budget and personal factors.
What is Island Pharmaceuticals fiscal year?
Island Pharmaceuticals’ fiscal year runs from July 1 to June 30.
Who maintains Island Pharmaceuticals’ share registry?
Automic Registry Services is Island Pharmaceuticals’ share registrar. Should you require information regarding your shareholding, please contact Automic via phone or web:
1300 288 664 (within Australia)
+61 (0) 2 9698 5414 (International)
What is the best way to keep across Island Pharmaceuticals’ progress?
A great way to keep across our news as it’s released to market is to subscribe for email alerts. To subscribe now, click here. You can unsubscribe at any time.
How do I contact Investor Relations?
For investor relations, refer details on our Contact Us page.